Diabetes Insights - Breakthroughs and Innovators

In this episode, Prof. Gill Livingston (University College London) and Prof. Thomas van Sloten (UMC Utrecht) explore the complex relationship between diabetes and dementia. People with diabetes face a higher risk of cognitive decline, particularly those with type 2 diabetes, and as treatment improves and life expectancy increases, dementia is becoming a growing clinical challenge.

The discussion examines how diabetes medications, including GLP-1 receptor agonists and SGLT2 inhibitors, may influence cognitive outcomes, the role of lifestyle and vascular risk factors, and why prevention must become central to diabetes care.

This episode also highlights the urgent need for clinical trials that include dementia and cognition as primary outcomes.

In this episode, Professor Francesco Giorgino (EASD President) and Professor Leszek Czupryniak (EASD Global Council Advisor) introduce EASD's newest initiative: the Global Council, launched in Madrid in 2023. This 13-member council brings together diabetes experts from Asia, North and South America, Africa, the Middle East, Australia, and underrepresented regions of Europe to provide direct, active contributions to EASD activities and address global challenges in diabetes research and care.

The conversation addresses the urgent importance of diversity in diabetes data and research, particularly as political movements in some regions actively discourage it and explains how registries are essential for understanding diabetes epidemiology and care delivery across different contexts.

Listen in to hear the announcement of a historic milestone: EASD's first new prize in nearly 60 years: the inaugural Global Impact Prize for Diabetes was awarded to Dr. Viswanathan Mohan from India for pioneering work in diabetes epidemiology and subtypes in Asia in 2025. Looking forward, the council is developing global structures for registries, supporting research development in underserved regions, and moving from hopes to concrete solutions.

In this episode, a cardiologist, an epidemiologist and a diabetologist come together to discuss the deep and evolving links between diabetes and cardiovascular disease. The conversation explores heart failure as a common but often under-recognized complication of diabetes, how cardiovascular risk begins even before type 2 diabetes develops, and why modern therapies increasingly target multiple organs at once. The speakers highlight the importance of early detection, collaboration across specialties, and prevention as populations age and chronic disease patterns shift.

In this episode, Prof. Frédéric Gachon and Prof. Olga Pivovarova-Ramich explore how the timing of eating and exercise influences metabolism and diabetes risk. Drawing on recent research in chronobiology, they discuss circadian rhythms, chronotype, late-night eating, intermittent fasting, and how aligning daily behaviours with our internal clocks may improve metabolic health and insulin sensitivity.

Prof. Gachon and and Prof. Pivovarova-Ramich explore how eating late or at the wrong time disrupts your body’s rhythm, and how different chronotypes (early risers vs night owls) respond to meal timing. They also touch on the growing popularity of intermittent fasting and time-restricted eating, as well as exercise timing and its connection to performance and sleep.

Listen in now to understand how the timing of diet and exercise can improve health outcomes, especially for individuals living with diabetes.

In this weeks episode of Diabetes Insights - Breakthroughs and Innovators, experts discuss the highly anticipated SURPASS CVOT trial, a head-to-head cardiovascular outcomes study comparing tirzepatide 15 mg weekly with dulaglutide 1.5 mg weekly in people with type 2 diabetes. With over 13,000 participants, the trial demonstrates that tirzepatide provides equivalent cardioprotective benefits to dulaglutide, confirming its role in improving both glycaemic control and cardiovascular outcomes.

EASD TV Host Vivienne Parry sits with Prof. Tina Vilsbøll (EASD Honorary Secretary) and Prof. Hertzel Gerstein (EASD Independent Advisor and McMaster University) to unpack the trial’s implications for clinical practice, highlighting how outcomes trials like this inform personalised medicine, integrate care between diabetologists and cardiologists, and generate new hypotheses in areas such as liver disease, cognitive function, and obesity management. This episode underscores the growing importance of transdisciplinary approaches in diabetes care, where therapies can target multiple complications simultaneously.

Join us to understand how outcomes trials like SURPASS-CVOT are shaping guidelines, expanding treatment options, and improving care for people living with type 2 diabetes worldwide.